Business Context and Reporting Period
This Form 6-K is filed by pSivida Limited, a foreign issuer, for the month of September 2005. The report was signed on September 15, 2005, by Aaron Finlay, Chief Financial Officer and Company Secretary. The registrant's principal executive offices are located in Perth, Western Australia.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report serves as a notification of a corporate event rather than a financial statement.
Material Changes and Corporate Events
The primary material event disclosed in this filing is the completion of manufacturing infrastructure for the company's BrachySilTM cancer therapy. This development is detailed in Exhibit 99.1 attached to the report.
Guidance, Outlook, and Risks
The filing text does not contain specific financial guidance, management commentary on future performance, or a discussion of risks and contingencies beyond the announcement of the infrastructure completion.
Investor Verification Points
- Verify the operational status and regulatory approval timeline for the BrachySilTM therapy following the infrastructure completion.
- Review the full text of Exhibit 99.1 for details on the manufacturing capabilities and associated costs.
- Confirm the company's current cash position and funding requirements to support the new manufacturing operations, as these figures are not included in this summary filing.